Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review
Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
Eisai Co Ltd Key Recent Developments
Sep 14,2021: Eisai to join the Global Environmental Initiative “RE100”
Aug 05,2021: Eisai receives award for excellence in corporate communications at the 37th corporate communications awards
Aug 04,2021: Notification regarding revision of consolidated financial forecasts (IFRS) for the fiscal year ending March 31, 2022
Jul 29,2021: Eisai listed for 20th consecutive year in FTSE4GOOD index series, an index for socially responsible investment
Jul 21,2021: Eisai to present latest data on pipeline assets in the area of Alzheimer’s disease and dementia at the Alzheimer’s Association International Conference (AAIC) 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
Eisai Co Ltd Key Recent Developments
Sep 14,2021: Eisai to join the Global Environmental Initiative “RE100”
Aug 05,2021: Eisai receives award for excellence in corporate communications at the 37th corporate communications awards
Aug 04,2021: Notification regarding revision of consolidated financial forecasts (IFRS) for the fiscal year ending March 31, 2022
Jul 29,2021: Eisai listed for 20th consecutive year in FTSE4GOOD index series, an index for socially responsible investment
Jul 21,2021: Eisai to present latest data on pipeline assets in the area of Alzheimer’s disease and dementia at the Alzheimer’s Association International Conference (AAIC) 2021
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Eisai Co Ltd - Key Facts
Eisai Co Ltd - Key Employees
Eisai Co Ltd - Key Employee Biographies
Eisai Co Ltd - Major Products and Services
Eisai Co Ltd - History
Eisai Co Ltd - Company Statement
Eisai Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Eisai Co Ltd - Business Description
Product Category: Neurology Products
Overview
Performance
Product Category: Oncology Products
Overview
Performance
Product Category: Others
Performance
Product Category: Americas Pharmaceutical Business
Overview
Performance
Target Markets
Product Category: Asia and Latin America Pharmaceutical Business
Overview
Performance
Target Markets
Product Category: China Pharmaceutical Business
Overview
Performance
Product Category: EMEA Pharmaceutical Business
Overview
Performance
Target Markets
Product Category: Japan Pharmaceutical Business
Overview
Performance
Product Category: OTC and Others
Overview
Product Category: OTC and Others Business
Performance
Product Category: Other Business
Overview
Performance
Geographical Segment: Americas
Target Markets
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Target Markets
Performance
R&D Overview
Eisai Co Ltd - Corporate Strategy
Eisai Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Eisai Co Ltd - Strengths
Eisai Co Ltd - Weaknesses
Eisai Co Ltd - Opportunities
Eisai Co Ltd - Threats
Eisai Co Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eisai Co Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 14, 2021: Eisai to join the Global Environmental Initiative “RE100”
Aug 05, 2021: Eisai receives award for excellence in corporate communications at the 37th corporate communications awards
Aug 04, 2021: Notification regarding revision of consolidated financial forecasts (IFRS) for the fiscal year ending March 31, 2022
Jul 29, 2021: Eisai listed for 20th consecutive year in FTSE4GOOD index series, an index for socially responsible investment
Jul 21, 2021: Eisai to present latest data on pipeline assets in the area of Alzheimer’s disease and dementia at the Alzheimer’s Association International Conference (AAIC) 2021
Jun 09, 2021: Eisai receives special prize at Platinum Career Award 2021
Jun 09, 2021: Eisai to Present Latest DAYVIGO CIV Data at 35th Annual Virtual SLEEP 2021 Meeting
May 20, 2021: Eisai to present data on oncology pipeline and products at ASCO Annual Meeting
May 17, 2021: Eisai data at ASCO 2021 highlight breadth of oncology portfolio across various tumor types
May 11, 2021: Eisai's Statement of Commitment for Carbon Neutrality by 2040
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Eisai Co Ltd - Key Facts
Eisai Co Ltd - Key Employees
Eisai Co Ltd - Key Employee Biographies
Eisai Co Ltd - Major Products and Services
Eisai Co Ltd - History
Eisai Co Ltd - Company Statement
Eisai Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Eisai Co Ltd - Business Description
Product Category: Neurology Products
Overview
Performance
Product Category: Oncology Products
Overview
Performance
Product Category: Others
Performance
Product Category: Americas Pharmaceutical Business
Overview
Performance
Target Markets
Product Category: Asia and Latin America Pharmaceutical Business
Overview
Performance
Target Markets
Product Category: China Pharmaceutical Business
Overview
Performance
Product Category: EMEA Pharmaceutical Business
Overview
Performance
Target Markets
Product Category: Japan Pharmaceutical Business
Overview
Performance
Product Category: OTC and Others
Overview
Product Category: OTC and Others Business
Performance
Product Category: Other Business
Overview
Performance
Geographical Segment: Americas
Target Markets
Performance
Geographical Segment: China
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Target Markets
Performance
R&D Overview
Eisai Co Ltd - Corporate Strategy
Eisai Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Eisai Co Ltd - Strengths
Eisai Co Ltd - Weaknesses
Eisai Co Ltd - Opportunities
Eisai Co Ltd - Threats
Eisai Co Ltd - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eisai Co Ltd, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 14, 2021: Eisai to join the Global Environmental Initiative “RE100”
Aug 05, 2021: Eisai receives award for excellence in corporate communications at the 37th corporate communications awards
Aug 04, 2021: Notification regarding revision of consolidated financial forecasts (IFRS) for the fiscal year ending March 31, 2022
Jul 29, 2021: Eisai listed for 20th consecutive year in FTSE4GOOD index series, an index for socially responsible investment
Jul 21, 2021: Eisai to present latest data on pipeline assets in the area of Alzheimer’s disease and dementia at the Alzheimer’s Association International Conference (AAIC) 2021
Jun 09, 2021: Eisai receives special prize at Platinum Career Award 2021
Jun 09, 2021: Eisai to Present Latest DAYVIGO CIV Data at 35th Annual Virtual SLEEP 2021 Meeting
May 20, 2021: Eisai to present data on oncology pipeline and products at ASCO Annual Meeting
May 17, 2021: Eisai data at ASCO 2021 highlight breadth of oncology portfolio across various tumor types
May 11, 2021: Eisai's Statement of Commitment for Carbon Neutrality by 2040
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Eisai Co Ltd, Key Facts
Eisai Co Ltd, Key Employees
Eisai Co Ltd, Key Employee Biographies
Eisai Co Ltd, Major Products and Services
Eisai Co Ltd, History
Eisai Co Ltd, Other Locations
Eisai Co Ltd, Subsidiaries
Eisai Co Ltd, Key Competitors
Eisai Co Ltd, Ratios based on current share price
Eisai Co Ltd, Annual Ratios
Eisai Co Ltd, Annual Ratios (Cont...1)
Eisai Co Ltd, Annual Ratios (Cont...2)
Eisai Co Ltd, Interim Ratios
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eisai Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Eisai Co Ltd, Key Facts
Eisai Co Ltd, Key Employees
Eisai Co Ltd, Key Employee Biographies
Eisai Co Ltd, Major Products and Services
Eisai Co Ltd, History
Eisai Co Ltd, Other Locations
Eisai Co Ltd, Subsidiaries
Eisai Co Ltd, Key Competitors
Eisai Co Ltd, Ratios based on current share price
Eisai Co Ltd, Annual Ratios
Eisai Co Ltd, Annual Ratios (Cont...1)
Eisai Co Ltd, Annual Ratios (Cont...2)
Eisai Co Ltd, Interim Ratios
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eisai Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Eisai Co Ltd, Performance Chart (2017 - 2021)
Eisai Co Ltd, Ratio Charts
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Eisai Co Ltd, Performance Chart (2017 - 2021)
Eisai Co Ltd, Ratio Charts
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021